In a small cell therapy trial, 10 out of 12 people with type 1 diabetes no longer needed supplemental insulin, even a year after treatment.

The U.S. Centers for Medicare & Medicaid Services posted the draft home health rule for calendar year 2026, which includes a proposal to subject continuous glucose monitors and insulin pumps to ...

The diabetes conference featured a debate about over-the-counter glucose monitors and updates on upcoming devices, including ...

People with diabetes may use insulin pens, wearable pump devices, or a glass vial and syringe to deliver this needed medication. Costs vary depending on which method you choose. The price of ...

Average age was 59, around half were women, 69% were white, and median duration of diabetes was 18 years. Those using an insulin pump before the trial were just 4%, whereas 71% were already using CGM.

MARKHAM, Ontario — Tandem Diabetes Care, Inc. (Nasdaq: TNDM) and Dexcom, Inc. today announced that following the recent authorization of sale by Health Canada, in-warranty t:slim X2™ insulin pump ...

Three drug companies dominate the U.S. insulin market: Novo Nordisk, Eli Lilly and Sanofi. Last spring, Eli Lilly reported its drugs Humalog and insulin lispro were in short supply.

The t:slim X2 pump is already approved for use with several U-100 insulins, including Humalog and Novolog/NovoRapid globally, as well as Admelog/Insulin lispro Sanofi and Trurapi/Insulin aspart Sanofi ...

The t:slim X2 pump is currently cleared for use with Humalog and Novolog/NovoRapid U-100 insulins globally, and Admelog/Insulin lispro Sanofi and Trurapi/Insulin aspart Sanofi U-100 insulins in ...

Previously, the t:slim X2 pump had clearance for use with Humalog and Novolog/NovoRapid U-100 insulins globally. It also had approval for Admelog/Insulin lispro Sanofi and Trurapi/Insulin aspart ...

Insulin revenue is “effectively immaterial in the wake of incretin and novel candidate prospects,” said David Risinger, a Leerink analyst who covers Lilly, referring to the class of GLP-1 drugs.